Jung-Min Lee, M.D.
Dr. Lee’s research is focused on the early clinical drug development and translational studies of targeted agents in BRCA mutation-associated breast or ovarian cancer, high-grade epithelial ovarian cancer, and triple negative breast cancer, as these diseases share the similar molecular abnormalities. Her clinical and translational research interests include examining the hypothesis of clinical synergy of the combination of targeting key proteins in the DNA damage repair pathways, cell cycle, tumor microenvironment, and immune check points in clinical trials, incorporating collected patient tissue and blood samples. She is the principal investigator of ongoing phase 1 and 2 studies, with a PARP inhibitor (olaparib) in combination with carboplatin or cediranib, and other biologic agents.
Phase IIB Study of Cediranib and Olaparib Combination in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Fallopian Tubal and/or Primary Peritoneal Cancer without Germline BRCA Mutation, Who Had Prior Bevacizumab (D8488C0001)Open - Not yet RecruitingNCI Protocol ID NCI-17-C-0172Investigator Jung-Min Lee, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Erin Nichols, BSN, RN 240-760-6131
Open - RecruitingNCI Protocol ID NCI-16-C-0073Investigator Jung-Min Lee, M.D.
Phase I/II Study of the Anti-programmed Death Ligand-1 Antibody MEDI4736 in Combination with Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersOpen - RecruitingNCI Protocol ID NCI-15-C-0145Investigator Jung-Min Lee, M.D.
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerOpen - RecruitingNCI Protocol ID NCI-14-C-0156Investigator Jung-Min Lee, M.D.
Dr. Lee's research interests include the early clinical drug development and translational studies of targeted agents in triple negative breast cancer (TNBC) and ovarian cancer, as these diseases share the similar molecular abnormalities, such as TP53 and Rb mutations. Her translational and clinical research interests include examining the hypothesis of clinical synergy of the combination of targeting key proteins in the DNA damage repair pathways, cell cycle, tumor microenvironment, and apoptotic pathways in clinical trials, incorporating collected patient tissue and blood samples. She is the principal investigator of ongoing phase 1 and 2 studies, with a PARP inhibitor (olaparib) in combination with carboplatin or cediranib, and other biologic agents. Dr. Lee's ASCO Young Investigator Award project is to test hypothesis of underlying sequence specificity of DNA damage by a PARP inhibitor and carboplatin, both at the preclinical and clinical levels. In addition, her New York Ovarian Cancer Research Award project is to develop a flow cytometric method to examine potential biomarkers of response to PARP inhibitor therapy in high-grade ovarian cancer. Dr. Lee's group is also interested in pursuing other potential biomarkers of response to targeted agents for cell cycle, apoptotic pathways, and targeted pathways pertinent to TNBC and high-grade serous ovarian cancer. She looks forward to advancing the preclinical biomarker and activity data into new clinical studies for women's cancers.
Selected Key Publications
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.J National Cancer Inst. 106(6): dju089, 2014. [ Journal Article ]
- Lancet Oncol. 15(11): 1207-14, 2014. [ Journal Article ]
Development of a dual-labeled flow cytometric as a predictive biomarker assay for response to PARP Inhibitor therapy in high-grade serous ovarian cancer.J Transl Med. 3: 239, 2015. [ Journal Article ]
Sequence-specific pharmacokinetic and pharmacodynamics phase I/Ib study of olaparib tablets and carboplatin in women’s cancer.Clin Cancer Res. 23(6): 1397-1406, 2017. [ Journal Article ]
Safety and Clinical Activity of the PD-L1 Inhibitor Durvalumab in Combination With a PARP Inhibitor, Olaparib, or a VEGFR1-3 Inhibitor, Cediranib, in Women's Cancers: A Dose-Escalation, Phase I Study.J Clin Oncol. 35(19): 2193-2202, 2017. [ Journal Article ]
Dr. Lee is a graduate of Yonsei University, Wonju College of Medicine in South Korea. She completed residency training in internal medicine at the Albert Einstein Medical College, followed by a clinical research fellowship on breast cancer functional imaging at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Lee came to the NCI for medical oncology training in the Medical Oncology Branch (MOB). Subsequently, she joined the Molecular Signaling Section/Women's Cancers Clinic, MOB, to investigate potential biomarkers and develop rational combinations of targeted therapies for rare subsets of women's cancers. Dr. Lee maintains her clinical focus in the development of early clinical trials for ovarian cancer and rare subsets of women's cancers, such as BRCA1/2mut carriers with ovarian and/or breast cancers, or women with triple negative breast cancer (TNBC). Dr. Lee is a participating member in the Gynecologic Oncology Group, American Association for Cancer Research, American Society for Clinical Oncology, and the Breast and Gynecologic Malignancies Faculty of the CCR. She was awarded the 2011 Jane C. Wright M.D. Young Investigator Award from the American Society of Clinical Oncology and the 2012 New York Ovarian Cancer Research Award from the Foundation for Women's Cancers.
|Dana-Adriana Botesteanu B.S.||Postbaccalaureate Fellow (CRTA)|
|Ethan S. Brill B.S.||Postbaccalaureate Fellow (CRTA)|
|Irene B. Ekwede R.N.||Clinical Research Nurse|
|Brittany Haynes Ph.D.||Postdoctoral Fellow (CRTA)|
|Nicole D. Houston R.N.||Clinical Research Nurse|
|Tzu-Ting Huang Ph.D.||Postdoctoral Fellow (CRTA)|
|Jayakumar Nair Ph.D.||Scientist (Contr)|
|Takuhei Yokoyama M.D., Ph.D.||Postdoctoral Fellow (CRTA)|
|Minshu Yu M.D., Ph.D.||Research Biologist|